Focus on hypertension and overall cardiovascular risk: a report from the 21st scientific meeting of the International Society of Hypertension.
Rabasseda
X
X
Medical Information Department, Prous Science.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004032:Diet; D006801:Humans; D006973:Hypertension / Q000628:therapy*; D054755:Imidazoline Receptors / Q000037:antagonists & inhibitors; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use; D000092502:Renin Inhibitors
D000317:Adrenergic alpha-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D054755:Imidazoline Receptors; D000451:Mineralocorticoid Receptor Antagonists; D011480:Protease Inhibitors; D000092502:Renin Inhibitors